Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data

Philip A. Poole-Wilson, Bridget Anne Kirwan, Z. Vokó, Sophie de Brouwer, Peter H J M Dunselman, Frederik J. van Dalen, Jacobus Lubsen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Objective: Published clinical trial data rarely allow assessment of the health care resource utilization implications of treatment. We give an example of how these can be assessed given appropriate tabulation of data. Methods: Data from a trial comparing long-acting nifedipine gastrointestinal therapeutic system to placebo in 7,665 patients with stable angina pectoris was analyzed. Results: Relative to placebo, nifedipine significantly increased mean cardiovascular (CV) event-free survival by 41 days but had no effect on mean survival. Per 100 years of follow-up, 78.1 patient-years of double-blind nifedipine administration reduced use of another calcium antagonist, an angiotensin converting enzyme inhibitor, an angiotensin receptor blocker, a diuretic and a cardiac glycoside by 1.54, 3.73, 2.63, 2.23, and 0.64 years, respectively, whereas 0.21 less hospitalization for overt heart failure, 0.47 less hospitalization for any stroke or transient ischemic attack, 0.8 less coronary angiogram, 0.38 less coronary bypass procedure, and 0.13 additional orthopedic procedure was required. Combining resource utilization with cost data for one particular hospital showed that one additional year of CV event-free survival costs an average additional €3,036 in the setting considered. Conclusion: Appropriately tabulated clinical trial data allows clinicians to judge the resource utilization implications and economic effect of treatment decisions.

Original languageEnglish
Pages (from-to)727-733
Number of pages7
JournalJournal of Clinical Epidemiology
Volume60
Issue number7
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Nifedipine
Clinical Trials
Disease-Free Survival
Hospitalization
Patient Acceptance of Health Care
Placebos
Orthopedic Procedures
Costs and Cost Analysis
Cardiac Glycosides
Stable Angina
Health Resources
Angiotensin Receptor Antagonists
Transient Ischemic Attack
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Angiography
Therapeutics
Heart Failure
Stroke
Economics

Keywords

  • Angina pectoris
  • Data analysis and reporting
  • Drug therapy
  • Health economics
  • Randomized clinical trials
  • Resource utilization

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data. / Poole-Wilson, Philip A.; Kirwan, Bridget Anne; Vokó, Z.; de Brouwer, Sophie; Dunselman, Peter H J M; van Dalen, Frederik J.; Lubsen, Jacobus.

In: Journal of Clinical Epidemiology, Vol. 60, No. 7, 07.2007, p. 727-733.

Research output: Contribution to journalArticle

Poole-Wilson, Philip A. ; Kirwan, Bridget Anne ; Vokó, Z. ; de Brouwer, Sophie ; Dunselman, Peter H J M ; van Dalen, Frederik J. ; Lubsen, Jacobus. / Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data. In: Journal of Clinical Epidemiology. 2007 ; Vol. 60, No. 7. pp. 727-733.
@article{99909346abfb4872857da1bb6130bc4c,
title = "Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data",
abstract = "Background and Objective: Published clinical trial data rarely allow assessment of the health care resource utilization implications of treatment. We give an example of how these can be assessed given appropriate tabulation of data. Methods: Data from a trial comparing long-acting nifedipine gastrointestinal therapeutic system to placebo in 7,665 patients with stable angina pectoris was analyzed. Results: Relative to placebo, nifedipine significantly increased mean cardiovascular (CV) event-free survival by 41 days but had no effect on mean survival. Per 100 years of follow-up, 78.1 patient-years of double-blind nifedipine administration reduced use of another calcium antagonist, an angiotensin converting enzyme inhibitor, an angiotensin receptor blocker, a diuretic and a cardiac glycoside by 1.54, 3.73, 2.63, 2.23, and 0.64 years, respectively, whereas 0.21 less hospitalization for overt heart failure, 0.47 less hospitalization for any stroke or transient ischemic attack, 0.8 less coronary angiogram, 0.38 less coronary bypass procedure, and 0.13 additional orthopedic procedure was required. Combining resource utilization with cost data for one particular hospital showed that one additional year of CV event-free survival costs an average additional €3,036 in the setting considered. Conclusion: Appropriately tabulated clinical trial data allows clinicians to judge the resource utilization implications and economic effect of treatment decisions.",
keywords = "Angina pectoris, Data analysis and reporting, Drug therapy, Health economics, Randomized clinical trials, Resource utilization",
author = "Poole-Wilson, {Philip A.} and Kirwan, {Bridget Anne} and Z. Vok{\'o} and {de Brouwer}, Sophie and Dunselman, {Peter H J M} and {van Dalen}, {Frederik J.} and Jacobus Lubsen",
year = "2007",
month = "7",
doi = "10.1016/j.jclinepi.2006.10.016",
language = "English",
volume = "60",
pages = "727--733",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data

AU - Poole-Wilson, Philip A.

AU - Kirwan, Bridget Anne

AU - Vokó, Z.

AU - de Brouwer, Sophie

AU - Dunselman, Peter H J M

AU - van Dalen, Frederik J.

AU - Lubsen, Jacobus

PY - 2007/7

Y1 - 2007/7

N2 - Background and Objective: Published clinical trial data rarely allow assessment of the health care resource utilization implications of treatment. We give an example of how these can be assessed given appropriate tabulation of data. Methods: Data from a trial comparing long-acting nifedipine gastrointestinal therapeutic system to placebo in 7,665 patients with stable angina pectoris was analyzed. Results: Relative to placebo, nifedipine significantly increased mean cardiovascular (CV) event-free survival by 41 days but had no effect on mean survival. Per 100 years of follow-up, 78.1 patient-years of double-blind nifedipine administration reduced use of another calcium antagonist, an angiotensin converting enzyme inhibitor, an angiotensin receptor blocker, a diuretic and a cardiac glycoside by 1.54, 3.73, 2.63, 2.23, and 0.64 years, respectively, whereas 0.21 less hospitalization for overt heart failure, 0.47 less hospitalization for any stroke or transient ischemic attack, 0.8 less coronary angiogram, 0.38 less coronary bypass procedure, and 0.13 additional orthopedic procedure was required. Combining resource utilization with cost data for one particular hospital showed that one additional year of CV event-free survival costs an average additional €3,036 in the setting considered. Conclusion: Appropriately tabulated clinical trial data allows clinicians to judge the resource utilization implications and economic effect of treatment decisions.

AB - Background and Objective: Published clinical trial data rarely allow assessment of the health care resource utilization implications of treatment. We give an example of how these can be assessed given appropriate tabulation of data. Methods: Data from a trial comparing long-acting nifedipine gastrointestinal therapeutic system to placebo in 7,665 patients with stable angina pectoris was analyzed. Results: Relative to placebo, nifedipine significantly increased mean cardiovascular (CV) event-free survival by 41 days but had no effect on mean survival. Per 100 years of follow-up, 78.1 patient-years of double-blind nifedipine administration reduced use of another calcium antagonist, an angiotensin converting enzyme inhibitor, an angiotensin receptor blocker, a diuretic and a cardiac glycoside by 1.54, 3.73, 2.63, 2.23, and 0.64 years, respectively, whereas 0.21 less hospitalization for overt heart failure, 0.47 less hospitalization for any stroke or transient ischemic attack, 0.8 less coronary angiogram, 0.38 less coronary bypass procedure, and 0.13 additional orthopedic procedure was required. Combining resource utilization with cost data for one particular hospital showed that one additional year of CV event-free survival costs an average additional €3,036 in the setting considered. Conclusion: Appropriately tabulated clinical trial data allows clinicians to judge the resource utilization implications and economic effect of treatment decisions.

KW - Angina pectoris

KW - Data analysis and reporting

KW - Drug therapy

KW - Health economics

KW - Randomized clinical trials

KW - Resource utilization

UR - http://www.scopus.com/inward/record.url?scp=34249991174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249991174&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2006.10.016

DO - 10.1016/j.jclinepi.2006.10.016

M3 - Article

VL - 60

SP - 727

EP - 733

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 7

ER -